SG11201808592PA - Method for selection of high m6p recombinant proteins - Google Patents
Method for selection of high m6p recombinant proteinsInfo
- Publication number
- SG11201808592PA SG11201808592PA SG11201808592PA SG11201808592PA SG11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- human lysosomal
- cranbury
- march
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315400P | 2016-03-30 | 2016-03-30 | |
| US201762457584P | 2017-02-10 | 2017-02-10 | |
| US15/473,994 US10227577B2 (en) | 2016-03-30 | 2017-03-30 | Method for selection of high M6P recombinant proteins |
| PCT/US2017/024981 WO2017173059A1 (en) | 2016-03-30 | 2017-03-30 | Method for selection of high m6p recombinant proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808592PA true SG11201808592PA (en) | 2018-10-30 |
Family
ID=58640993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808592PA SG11201808592PA (en) | 2016-03-30 | 2017-03-30 | Method for selection of high m6p recombinant proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10227577B2 (ja) |
| JP (3) | JP7046003B2 (ja) |
| KR (3) | KR20220145918A (ja) |
| AU (2) | AU2017239640B2 (ja) |
| BR (1) | BR112018070189A2 (ja) |
| CA (1) | CA3019354A1 (ja) |
| CL (1) | CL2018002767A1 (ja) |
| IL (2) | IL262060B (ja) |
| MX (3) | MX2018011951A (ja) |
| PE (1) | PE20190127A1 (ja) |
| SG (1) | SG11201808592PA (ja) |
| WO (1) | WO2017173059A1 (ja) |
| ZA (2) | ZA201807184B (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102618519B1 (ko) * | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| IL262060B (en) * | 2016-03-30 | 2022-09-01 | Amicus Therapeutics Inc | A method for selecting recombinant proteins with a high amount of mannose-6-phosphate |
| TW201829770A (zh) * | 2017-01-10 | 2018-08-16 | 美商阿米庫斯醫療股份有限公司 | 用於治療fabry氏病之重組α-半乳糖苷酶A |
| HUE062504T2 (hu) * | 2017-05-15 | 2023-11-28 | Amicus Therapeutics Inc | Rekombináns humán savas alfa-glükozidáz |
| WO2021046443A1 (en) | 2019-09-06 | 2021-03-11 | Amicus Therapeutics, Inc. | Method for capturing and purification of biologics |
| EP3871687A1 (en) * | 2020-02-27 | 2021-09-01 | eleva GmbH | Enzyme replacement therapy for treating pompe disease |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| TW202400212A (zh) | 2022-05-05 | 2024-01-01 | 美商阿米庫斯醫療股份有限公司 | 用於治療龐貝氏病之方法 |
| WO2024119070A1 (en) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Methods for treating late onset pompe disease in pediatric patients |
| WO2024119091A1 (en) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Fexamethods for treating infantile-onset pompe disease in pediatric patients |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
| US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US20020073438A1 (en) * | 1995-08-02 | 2002-06-13 | Reuser Arnold J. | Methods of purifying human acid alpha-glucosidase |
| US20020013953A1 (en) * | 1995-08-02 | 2002-01-31 | Reuser Arnold J. | Compositions and methods for treating enzyme deficiency |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| MY122499A (en) | 1997-11-10 | 2006-04-29 | Searle & Co | Use of alkylated iminosugars to treat multidrug resistance |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| JP4990434B2 (ja) * | 1998-12-07 | 2012-08-01 | ジェンザイム・コーポレーション | ポンペ病の処置 |
| AU3595500A (en) | 1999-02-12 | 2000-08-29 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| EP1196190B1 (en) | 1999-07-26 | 2003-03-19 | G.D. SEARLE & CO. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases |
| US6642038B1 (en) | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| EP3449934B1 (en) | 2000-07-18 | 2020-05-20 | Duke University | Treatment of glycogen storage disease type ii |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| EP1974752B1 (en) | 2001-04-30 | 2012-09-26 | BioMarin Pharmaceutical Inc. | Subcellular targeting of therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US8372798B2 (en) | 2001-10-16 | 2013-02-12 | Endo Pharmaceuticals Colorado, Inc. | High-concentration protein formulations and method of manufacture |
| WO2003086452A2 (en) | 2002-04-05 | 2003-10-23 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
| CN1756558B (zh) | 2003-01-31 | 2012-04-25 | 纽约大学西奈山医学院 | 酶和酶的活性部位特异性陪伴分子的组合 |
| FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| WO2005077093A2 (en) * | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| US20050244400A1 (en) | 2004-02-10 | 2005-11-03 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| EP3441090A1 (en) * | 2005-05-17 | 2019-02-13 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| EP2099523A2 (en) | 2006-11-13 | 2009-09-16 | ZyStor Therapeutics , Inc. | Methods for treating pompe disease |
| WO2008112525A2 (en) | 2007-03-09 | 2008-09-18 | Link Medicine Corporation | Treatment of lysosomal storage diseases |
| US9056101B2 (en) | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US20100317690A1 (en) | 2007-11-21 | 2010-12-16 | Summit Corporation Plc | Treatment of protein folding disorders |
| WO2009075815A1 (en) | 2007-12-07 | 2009-06-18 | Duke University | Immunomodulating gene therapy |
| PT2946785T (pt) * | 2008-02-12 | 2019-02-01 | Amicus Therapeutics Inc | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| MX2010009874A (es) | 2008-03-12 | 2010-11-30 | Amicus Therapeutics Inc | Tratamiento para la enfermedad de pompe con chaperonas farmacologicas especificas y monitoreo del tratamiento usando marcadores subrogados. |
| US20110136151A1 (en) | 2008-03-12 | 2011-06-09 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for pompe disease |
| WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| US20100119502A1 (en) | 2008-11-11 | 2010-05-13 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
| CN103432566A (zh) | 2008-12-16 | 2013-12-11 | 建新公司 | 寡糖-蛋白缀合物 |
| EP2416656B1 (en) | 2009-04-09 | 2015-12-23 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating lysosomal storage disorders |
| US8785168B2 (en) | 2009-06-17 | 2014-07-22 | Biomarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| JP5990102B2 (ja) * | 2009-09-29 | 2016-09-07 | ユニフェルシテイト ヘント | ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解 |
| US20130196410A1 (en) | 2010-03-05 | 2013-08-01 | Alnylam Pharmaceuticals, Inc | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| SG189108A1 (en) * | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| JP2014513952A (ja) | 2011-04-22 | 2014-06-19 | ジェンザイム・コーポレーション | 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ |
| WO2013013017A2 (en) | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| JP6320931B2 (ja) | 2011-12-22 | 2018-05-09 | セントジーン アイピー ゲーエムベーハー | リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ |
| CA2866683A1 (en) | 2012-03-07 | 2013-09-12 | Amicus Therapeutics, Inc. | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
| AU2013234042B2 (en) * | 2012-03-15 | 2017-11-02 | Oxyrane Uk Limited | Methods and materials for treatment of Pompe's disease |
| WO2013166249A1 (en) | 2012-05-03 | 2013-11-07 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of pompe disease |
| WO2013182652A1 (en) | 2012-06-06 | 2013-12-12 | Fondazione Telethon | Allosteric chaperones and uses thereof |
| CN114540327A (zh) | 2014-09-30 | 2022-05-27 | 阿米库斯治疗学公司 | 具有增强的碳水化合物的高强度酸性α-葡糖苷酶 |
| IL262060B (en) * | 2016-03-30 | 2022-09-01 | Amicus Therapeutics Inc | A method for selecting recombinant proteins with a high amount of mannose-6-phosphate |
-
2017
- 2017-03-30 IL IL262060A patent/IL262060B/en unknown
- 2017-03-30 AU AU2017239640A patent/AU2017239640B2/en active Active
- 2017-03-30 SG SG11201808592PA patent/SG11201808592PA/en unknown
- 2017-03-30 IL IL295551A patent/IL295551A/en unknown
- 2017-03-30 US US15/473,994 patent/US10227577B2/en active Active
- 2017-03-30 MX MX2018011951A patent/MX2018011951A/es unknown
- 2017-03-30 BR BR112018070189-0A patent/BR112018070189A2/pt unknown
- 2017-03-30 PE PE2018001915A patent/PE20190127A1/es unknown
- 2017-03-30 WO PCT/US2017/024981 patent/WO2017173059A1/en active Application Filing
- 2017-03-30 KR KR1020227035616A patent/KR20220145918A/ko not_active Application Discontinuation
- 2017-03-30 KR KR1020217041615A patent/KR102455821B1/ko active IP Right Grant
- 2017-03-30 JP JP2018551350A patent/JP7046003B2/ja active Active
- 2017-03-30 KR KR1020187030848A patent/KR102343162B1/ko active IP Right Grant
- 2017-03-30 CA CA3019354A patent/CA3019354A1/en active Pending
-
2018
- 2018-09-28 MX MX2022014533A patent/MX2022014533A/es unknown
- 2018-09-28 MX MX2022014532A patent/MX2022014532A/es unknown
- 2018-09-28 CL CL2018002767A patent/CL2018002767A1/es unknown
- 2018-10-26 ZA ZA2018/07184A patent/ZA201807184B/en unknown
-
2019
- 2019-01-18 US US16/252,519 patent/US11441138B2/en active Active
-
2020
- 2020-10-23 ZA ZA2020/06604A patent/ZA202006604B/en unknown
-
2022
- 2022-03-22 JP JP2022044814A patent/JP7436545B2/ja active Active
- 2022-09-12 US US17/931,351 patent/US20230079225A1/en active Pending
- 2022-10-27 AU AU2022259797A patent/AU2022259797B2/en active Active
-
2024
- 2024-02-08 JP JP2024017546A patent/JP2024063015A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022259797A1 (en) | 2022-12-01 |
| US10227577B2 (en) | 2019-03-12 |
| US11441138B2 (en) | 2022-09-13 |
| JP2019509754A (ja) | 2019-04-11 |
| AU2017239640A1 (en) | 2018-10-25 |
| ZA202006604B (en) | 2023-04-26 |
| US20230079225A1 (en) | 2023-03-16 |
| JP2024063015A (ja) | 2024-05-10 |
| IL262060A (en) | 2018-11-29 |
| KR20210157477A (ko) | 2021-12-28 |
| KR102455821B1 (ko) | 2022-10-18 |
| US20190382742A1 (en) | 2019-12-19 |
| KR20180128945A (ko) | 2018-12-04 |
| JP7046003B2 (ja) | 2022-04-01 |
| AU2017239640B2 (en) | 2022-07-28 |
| JP7436545B2 (ja) | 2024-02-21 |
| CA3019354A1 (en) | 2017-10-05 |
| AU2022259797B2 (en) | 2024-08-08 |
| PE20190127A1 (es) | 2019-01-17 |
| MX2022014532A (es) | 2022-12-13 |
| IL262060B (en) | 2022-09-01 |
| KR20220145918A (ko) | 2022-10-31 |
| BR112018070189A2 (pt) | 2019-02-19 |
| IL295551A (en) | 2022-10-01 |
| KR102343162B1 (ko) | 2021-12-23 |
| CL2018002767A1 (es) | 2019-01-11 |
| MX2022014533A (es) | 2022-12-13 |
| ZA201807184B (en) | 2021-02-24 |
| WO2017173059A1 (en) | 2017-10-05 |
| MX2018011951A (es) | 2019-02-13 |
| JP2022101545A (ja) | 2022-07-06 |
| US20170335301A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201806002SA (en) | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201408459VA (en) | Purification of virus like particles | |
| SG11201807134RA (en) | Transposon system and methods of use | |
| SG11201805001UA (en) | Method of treating influenza a |